Suppr超能文献

优化密码子的凝血因子 VIII 的表达和表征。

Expression and characterization of a codon-optimized blood coagulation factor VIII.

机构信息

Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.

Poochon Scientific, Frederick, MD, USA.

出版信息

J Thromb Haemost. 2017 Apr;15(4):709-720. doi: 10.1111/jth.13632. Epub 2017 Feb 21.

Abstract

UNLABELLED

Essentials Recombinant factor VIII (FVIII) is known to be expressed at a low level in cell culture. To increase expression, we used codon-optimization of a B-domain deleted FVIII (BDD-FVIII). This resulted in 7-fold increase of the expression level in cell culture. The biochemical properties of codon-optimized BDD-FVIII were similar to the wild-type protein.

SUMMARY

Background Production of recombinant factor VIII (FVIII) is challenging because of its low expression. It was previously shown that codon-optimization of a B-domain-deleted FVIII (BDD-FVIII) cDNA resulted in increased protein expression. However, it is well recognized that synonymous mutations may affect the protein structure and function. Objectives To compare biochemical properties of a BDD-FVIII variants expressed from codon-optimized and wild-type cDNAs (CO and WT, respectively). Methods Each variant of the BDD-FVIII was expressed in several independent Chinese hamster ovary (CHO) cell lines, generated using a lentiviral platform. The proteins were purified by two-step affinity chromatography and analyzed in parallel by PAGE-western blot, mass spectrometry, circular dichroism, surface plasmon resonance, and chromogenic, clotting and thrombin generation assays. Results and conclusion The average yield of the CO was 7-fold higher than WT, whereas both proteins were identical in the amino acid sequences (99% coverage) and very similar in patterns of the molecular fragments (before and after thrombin cleavage), glycosylation and tyrosine sulfation, secondary structures and binding to von Willebrand factor and to a fragment of the low-density lipoprotein receptor-related protein 1. The CO preparations had on average 1.5-fold higher FVIII specific activity (activity normalized to protein mass) than WT preparations, which was attributed to better preservation of the CO structure as a result of considerably higher protein concentrations during the production. We concluded that the codon-optimization of the BDD-FVIII resulted in significant increase of its expression and did not affect the structure-function properties.

摘要

未加标签

已知因子 VIII(FVIII)在细胞培养中表达水平较低。为了提高表达水平,我们使用 B 结构域缺失的 FVIII(BDD-FVIII)的密码子优化。这导致细胞培养中表达水平提高了 7 倍。密码子优化的 BDD-FVIII 的生化特性与野生型蛋白相似。

摘要

背景因子 VIII(FVIII)的表达具有挑战性,因为其表达水平较低。先前的研究表明,B 结构域缺失的 FVIII(BDD-FVIII)cDNA 的密码子优化导致蛋白表达增加。然而,人们普遍认识到同义突变可能会影响蛋白的结构和功能。目的比较来自密码子优化和野生型 cDNA(分别为 CO 和 WT)表达的 BDD-FVIII 变体的生化特性。方法使用慢病毒平台,在几个独立的中国仓鼠卵巢(CHO)细胞系中表达每种 BDD-FVIII 变体。通过两步亲和层析纯化蛋白,并通过 PAGE-免疫印迹、质谱、圆二色性、表面等离子体共振和显色、凝固和凝血酶生成分析平行分析。结果和结论 CO 的平均产量比 WT 高 7 倍,而两种蛋白的氨基酸序列完全相同(99%覆盖率),并且在分子片段的模式(凝血酶切割前后)、糖基化和酪氨酸硫酸化、二级结构和与 von Willebrand 因子以及 LDL 受体相关蛋白 1 的片段的结合方面非常相似。CO 制剂的 FVIII 比 WT 制剂具有平均高 1.5 倍的比活性(活性按蛋白质量归一化),这归因于在生产过程中 CO 结构得到了更好的保护,因为蛋白浓度大大提高。我们得出结论,BDD-FVIII 的密码子优化导致其表达显著增加,并且不影响结构-功能特性。

相似文献

8
Bioengineering of coagulation factor VIII for improved secretion.用于改善分泌的凝血因子 VIII 的生物工程。
Blood. 2004 May 1;103(9):3412-9. doi: 10.1182/blood-2003-10-3591. Epub 2004 Jan 15.

引用本文的文献

1
Advances in biopharmaceutical products for hemophilia.用于血友病的生物制药产品的进展。
iScience. 2024 Dec 3;27(12):111436. doi: 10.1016/j.isci.2024.111436. eCollection 2024 Dec 20.
2
Cellular stress and coagulation factor production: when more is not necessarily better.细胞应激与凝血因子生成:过犹不及。
J Thromb Haemost. 2023 Dec;21(12):3329-3341. doi: 10.1016/j.jtha.2023.10.005. Epub 2023 Oct 14.
5
The intersection of vector biology, gene therapy, and hemophilia.媒介生物学、基因治疗与血友病的交叉领域
Res Pract Thromb Haemost. 2021 Sep 1;5(6):e12586. doi: 10.1002/rth2.12586. eCollection 2021 Aug.
6
Immune Responses to Plasma-Derived Versus Recombinant FVIII Products.免疫对血浆衍生的与重组 FVIII 产品的反应。
Front Immunol. 2021 Jan 22;11:591878. doi: 10.3389/fimmu.2020.591878. eCollection 2020.
9
Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII.犬因子VIII中关键凝血活性决定因素的鉴定
Mol Ther Methods Clin Dev. 2020 Jan 15;17:328-336. doi: 10.1016/j.omtm.2019.12.019. eCollection 2020 Jun 12.
10
Production of Therapeutic Enzymes by Lentivirus Transgenesis.慢病毒转基因生产治疗性酶。
Adv Exp Med Biol. 2019;1148:25-54. doi: 10.1007/978-981-13-7709-9_2.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验